title: Age-dependent cognitive changes in carriers of the fragile X syndrome.
abstract: Fragile X syndrome is a neurodevelopmental disorder that is caused by the silencing of a single gene on the X chromosome, the fragile X mental retardation 1 (FMR1) gene. Affected individuals display a unique neurocognitive phenotype that includes significant impairment in inhibitory control, selective attention, working memory, and visual-spatial cognition. In contrast, little is known about the trajectory and specificity of any cognitive impairment associated with the fragile X premutation (i.e., "carrier status") or its relationship with the recently identified neurodegenerative disorder, fragile X-associated tremor/ataxia syndrome (FXTAS). In the present study, we evaluated a broad sample of 40 premutation males (PM) aged 18-69 years matched on age and IQ to 67 unaffected comparison males (NC). Performance was compared across a range of cognitive domains known to be impaired in fragile X syndrome (i.e., "full mutation"). Tremor was also assessed using a self-report neurological questionnaire. PM displayed statistically significant deficits in their ability to inhibit prepotent responses, differentiating them from NC from age 30 onwards. With increasing age, the two groups follow different trajectories, with PM developing progressively more severe problems in inhibitory control. This deficit also has a strong co-occurrence in males displaying FXTAS-related symptomatology (p<.001). Selective attention was also impaired in PM but did not show any disproportionate aging effect. No other cognitive deficits were observed. We conclude that an inhibitory deficit and its impact across the lifespan are specifically associated with the fragile X premutation status, and may be a precursor for development of a more severe form of cognitive impairment or dementia, which has been reported in patients with the diagnosis of FXTAS.
authors.affiliation: Neuroscience Laboratory for Research and Education in Developmental Disorders, McGill University, Montreal, Canada. kim.cornish@mcgill.ca
authors.forename: Kim M
authors.initials: KM
authors.lastname: Cornish
authors.forename: Lexin
authors.initials: L
authors.lastname: Li
authors.forename: Cary S
authors.initials: CS
authors.lastname: Kogan
authors.forename: Sebastien
authors.initials: S
authors.lastname: Jacquemont
authors.forename: Jeremy
authors.initials: J
authors.lastname: Turk
authors.forename: Ann
authors.initials: A
authors.lastname: Dalton
authors.forename: Randi J
authors.initials: RJ
authors.lastname: Hagerman
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Hagerman
mesh_terms: D000328:Adult; D000368:Aged; D000375:Aging / Q000235:genetics*; D001288:Attention / Q000502:physiology*; D016022:Case-Control Studies; D003071:Cognition / Q000502:physiology; D004252:DNA Mutational Analysis; D018450:Disease Progression; D051860:Fragile X Messenger Ribonucleoprotein 1 / Q000235:genetics; D005600:Fragile X Syndrome / Q000150:complications / Q000235:genetics* / Q000503:physiopathology / Q000523:psychology; D018628:Gene Dosage; D006579:Heterozygote; D006801:Humans; D007266:Inhibition, Psychological; D007360:Intelligence / Q000235:genetics; D008297:Male; D016555:Matched-Pair Analysis; D008875:Middle Aged; D009154:Mutation; D009483:Neuropsychological Tests; D025341:Principal Component Analysis; D012727:Sex Characteristics; D014202:Tremor / Q000150:complications / Q000175:diagnosis; D018911:Trinucleotide Repeats
chemical_list: D051860:Fragile X Messenger Ribonucleoprotein 1; C497683:FMR1 protein, human